Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Harvard Business School
Colorcon
Dow

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JANUMET

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Janumet

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00532935 MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) Completed Merck Sharp & Dohme Corp. Phase 3 2008-01-01 A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
NCT00684528 A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin Unknown status Clalit Health Services Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00684528 A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin Unknown status Meir Medical Center Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00993187 Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed Merck Sharp & Dohme Corp. Phase 4 2010-05-01 This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Janumet

Condition Name

Condition Name for Janumet
Intervention Trials
Type 2 Diabetes Mellitus 5
Diabetes Mellitus, Type 2 2
Polycystic Ovary Syndrome 1
Disorder of Glucose Regulation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Janumet
Intervention Trials
Diabetes Mellitus, Type 2 10
Diabetes Mellitus 9
Polycystic Ovary Syndrome 1
Body Weight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Janumet

Trials by Country

Trials by Country for Janumet
Location Trials
United States 9
Canada 5
Israel 2
Germany 2
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Janumet
Location Trials
Louisiana 1
Pennsylvania 1
Ohio 1
Michigan 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Janumet

Clinical Trial Phase

Clinical Trial Phase for Janumet
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Janumet
Clinical Trial Phase Trials
Completed 7
Recruiting 3
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Janumet

Sponsor Name

Sponsor Name for Janumet
Sponsor Trials
Merck Sharp & Dohme Corp. 8
Population Health Research Institute 1
Chinese University of Hong Kong 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Janumet
Sponsor Trials
Other 10
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
AstraZeneca
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.